Sensex
82,057.47 profit arw 695.60 (0.85%)
Nifty
25,004.85 profit arw 211.60 (0.85%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 17-Jun-2025
Hot Pursuit
17-Jun-2025     11:35

Hikal clears ANVISA GMP audit at Bengaluru API unit

The audit, which covered multiple active pharmaceutical ingredients (APIs), was conducted from 14 April to 18 April 2025.

The successful completion of the inspection reinforces Hikal's compliance with international quality standards and strengthens its position in regulated markets like Brazil.

Hikal is engaged in the business of pharmaceuticals, crop protection, and specialty chemicals.

The company's consolidated net profit rallied 48.08% to Rs 50.20 crore on 7.44% rise in revenue from operations to Rs 552.40 crore in Q4 FY25 over Q4 FY24.

Shares of Hikal rose 0.29% to Rs 377.10 on the BSE.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

82,057.47 695.60 (0.85%)

Nifty

25,004.85 211.60 (0.85%)

GLOBAL INDICES

USD

85.75 0.06 (0.95%)

NASDAQ
HANG SENG

23,237.75 -472.95(-1.99%)